An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes

J Neurol. 2006 Jan;253(1):16-20. doi: 10.1007/s00415-005-0882-0.


Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved > or =1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies / metabolism*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • ELAV Proteins / immunology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nerve Tissue Proteins / immunology
  • Paraneoplastic Syndromes, Nervous System / drug therapy*
  • Paraneoplastic Syndromes, Nervous System / immunology*
  • Rituximab
  • Treatment Outcome


  • Antibodies
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • CDR2 protein, human
  • ELAV Proteins
  • Nerve Tissue Proteins
  • Rituximab